Ambu A/s Class B · OMXCOP:AMBU_B
Ambu A/s Class B — Ambu A S Ord — Q3 2020 Earnings Presentation
20 slides from Ambu A/s Class B's earnings presentation, Aug 26, 2020
Slide 1: Investor presentation Q3 2019/20 results
Investor presentation Q3 2019/20 results
Slide 2: The world's most innovative single-use endoscopy player
The world’s most Business update innovative single-use Financial results and outlook endoscopy player Q&A Disclaimer Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s co
Slide 3: Uniquely positioned for value creation
Uniquely positioned for value creation Competitive advantages Unique market opportunity Global leader in single-use Visualization with I 10 years of experience II Competitive advantage in modular innovation $2.5B+ engine and high scale low-cost manufacturing single-use market opportunity by 2024 Com
Slide 4: Business update
Business update 4
Slide 5: Key messages
Key messages 1 The COVID-19 pandemic has accelerated the development of the single-use endoscopy market Healthcare systems have increased their focus on infection control and the medical community is actively evaluating contamination levels and see single-use endoscopy as an attractive solution
Slide 6: The case for single-use endoscopy continues to strengthen
1 The case for single-use endoscopy continues to strengthen INCREASED FOCUS ON UPDATED GUIDELINES FROM FDA INFECTION CONTROL AND NATIONAL ASSOCIATIONS Most recent peer-reviewed meta-analysis 2nd FDA safety communication recommending shows a +15% contamination rate transition to duodenoscopes with in
Slide 7: COVID-19 impact on Visualization has been positive, especially in Europe
2 COVID-19 impact on Visualization has been positive, especially in Europe Positive impact in Visualization Endoscope units sold (‘000) ▪ aScope™ 4 Broncho is an important part of +1,000 COVID-19 treatment in Europe and RoW with sales increasing +195% and +105% respectively ▪ We have seen high doubl
Slide 8: COVID-19 impact on Core business has been negative, especially in PMD
2 COVID-19 impact on Core business has been negative, especially in PMD Negative impact in Core Core, organic growth ▪ Postponement of elective procedures had Core PMD Anaesthesia significant negative impact in especially PMD 3% ▪ Strong demand for resuscitators to treat COVID-19 patients. Expansion
Slide 9: Advancing our innovation agenda in a COVID-19 environment
3 Advancing our innovation agenda in a COVID-19 environment Product Launch aView™ 2 Advance Commercially available Monitors aBox™ Console 2H, 2020/21 Launches in 2019/20 aScope™ 4 Broncho aScope BronchoSampler™ Successfully introduced VivaSight™ aView™ 2 Advance and Pulmonary aScope™ 5 HD Q4, 2020/2
Slide 10: Entering urology with the U.S. launch of aScope Cysto
3 Entering urology with the U.S. launch of aScope™ 4 Cysto Expect rapid uptake on the back of positive feedback Main highlight around overall scope performance and superior image resolution driven by advanced sensor, software and newest display technology platform, aView™ 2 Advance ~500 21 Product o
Slide 11: Entering into GI with the launch of aScope Duodeno
3 Entering into GI with the launch of aScope™ Duodeno aScope™ Duodeno was granted breakthrough designation Meta analysis and secured FDA clearance. Expect rapid market conversion I on the back of FDA safety communications and new TPT reimbursement payment from CMS Our controlled market release has s
Slide 12: Financial results and outlook
Financial results and outlook Disclaimer Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of the company to differ materially
Slide 13: Financial results Q3 2019/20
Financial results Q3 2019/20 Q3 21% 16.5% 337 2019/20 organic revenue EBIT margin Endoscopes sold growth before special items (‘000 units) Guidance ~26% ~12% +1,000 Full year 2019/20 organic revenue EBIT margin Endoscopes sold growth before special items (‘000 units) Previously 26-30% Previously 12-
Slide 14: Organic sales growth by geography
Organic sales growth by geography Q3 2019/20 revenue and growth across regions Global North America 57% 16% 81% Visualization -2% Visualization 947m 21% Anaesthesia 349m -10% Anaesthesia organic -1% organic -6% DKK revenue growth DKK revenue growth -32% PMD -43% PMD 27% Europe Rest of World 195% Vis
Slide 15: Financial results Q3 2019/20
Financial results Q3 2019/20 Reported growth of 23% and organic growth of 21% Ambu P&L – Q3 2019/20 21% organic growth Increased demand for Visualization Q3 Q3 Change products in certain geographies DKKm Change% 2019/20 2018/19 in value Revenue 947 773 174 23% Production costs -334 -337 3 -1% 64.7%
Slide 16: Cash flow, assets and debt Q3 2019/20
Cash flow, assets and debt Q3 2019/20 Milestone payment of EUR 40m relating to clearance of duodenoscope will mature in Q1 2020/21 Ambu cash flow and balance sheet – Q3 2019/20 Q3 Q3 Change in DKKm 2019/20 2018/19 value DKK 187m free cash flow Cash flow and ratios Down DKK 296m at DKK -92m for the f
Slide 17: 2019/20 Guidance
2019/20 Guidance ~26% ~12% + 1,000,000 Organic EBIT Endoscope growth margin units sold COVID-19 has significantly increased the demand for single-use scopes, especially in Europe Most Core products were negatively affected as elective procedures reduced sharply in April and May, but we see a gra
Slide 18: Conference call Q&A
Q&A Conference call DK: +45 3544 5577 UK: +44 3333 000 804 US: +1 631 913 1422 PIN code: 70317768# Please limit your questions to only 3 at a time and get back into the queue if you For questions, please press 01 have additional questions 18
Slide 19: Investor contact information
Investor contact information Share Information Financial calendar Ambu A/S is listed on the stock exchange in 2020 Copenhagen under the symbol AMBU B 11 November Q4 2019/20 For further company information, please visit: 09 December Annual General Meeting 2019/20 www.ambu.com For full list of Investo
Slide 20: Ambu – The single-use company
Ambu – The single-use company